医学
左旋甲状腺素
兴奋剂
甲状腺切除术
内科学
内分泌学
激素
甲状腺
甲状腺癌
甲状腺髓样癌
受体
作者
Lauren B. Wilcox,Elizabeth Van Dril
标识
DOI:10.1016/j.japh.2024.102185
摘要
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy has demonstrated an increased risk of thyroid C-cell hyperplasia and C-cell tumors in rodents. Due to this risk, a boxed warning for this drug class exists for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. There is a lack of data regarding any possible effect of GLP-1 RA therapy on serum thyroid levels. The objective of this case report is to describe a case of suppressed thyroid stimulating hormone levels after initiation of a subcutaneous semaglutide in a post-total thyroidectomy patient managed with levothyroxine in order to highlight the need for closer monitoring of these patients and further research in this area.
科研通智能强力驱动
Strongly Powered by AbleSci AI